Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Overactive Bladder
Interventions
COMBINATION_PRODUCT

ViXe Xombination

Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure

COMBINATION_PRODUCT

Placebo + Sham

Placebo identical in package and appearance to Xeomin together with all steps of Vibe device preparation and activation, but without the actual operation of the ultrasound energy

Trial Locations (8)

Unknown

CHUC, Coimbra

HSOG, Guimarães

CHLN, Lisbon

CHUSJ, Porto

Hospital Lusíadas, Porto

Hospital Prelada, Porto

Hospital Luz Setúbal, Setúbal

CHVNG, Vila Nova de Gaia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Blueclinical, Ltd.

OTHER

lead

Vensica Therapeutics Ltd.

INDUSTRY

NCT06345677 - Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects | Biotech Hunter | Biotech Hunter